Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Reviva Pharmaceuticals (NASDAQ: RVPH) has reported significant progress in its brilaroxazine development program for schizophrenia treatment, alongside Q2 2025 financial results. The company successfully completed its Phase 3 RECOVER open-label extension (OLE) 1-year study, demonstrating sustained efficacy across all symptom domains and a well-tolerated safety profile.
Key clinical achievements include robust broad-spectrum efficacy with improvements in PANSS total score (-18.1), positive symptoms (-5.0), and negative symptoms (-4.4). The company plans to meet with the FDA in Q4 2025 to discuss the path to approval, with a potential NDA submission targeted for Q2 2026.
Financially, Reviva reported a net loss of $6.1 million ($0.12 per share) for Q2 2025, compared to $7.9 million in Q2 2024. The company's cash position stands at $10.4 million, bolstered by a recent $10.0 million public equity offering.
Reviva Pharmaceuticals (NASDAQ: RVPH) ha annunciato progressi rilevanti nel suo programma di sviluppo di brilaroxazina per il trattamento della schizofrenia e ha comunicato i risultati finanziari del secondo trimestre 2025. L'azienda ha completato con successo lo studio di estensione in aperto (OLE) di 1 anno della Fase 3 RECOVER, dimostrando efficacia duratura su tutti i domini sintomatologici e un profilo di sicurezza ben tollerato.
I principali risultati clinici includono una solida efficacia ad ampio spettro con miglioramenti nel punteggio PANSS totale (-18,1), nei sintomi positivi (-5,0) e in quelli negativi (-4,4). La societ脿 prevede un incontro con la FDA nel quarto trimestre 2025 per discutere il percorso verso l'approvazione, con l'obiettivo di una possibile presentazione della NDA nel secondo trimestre 2026.
Sul fronte finanziario, Reviva ha registrato una perdita netta di 6,1 milioni di dollari (0,12$ per azione) nel Q2 2025, rispetto a 7,9 milioni nel Q2 2024. La liquidit脿 disponibile 猫 pari a 10,4 milioni di dollari, rafforzata da un recente aumento di capitale pubblico di 10,0 milioni di dollari.
Reviva Pharmaceuticals (NASDAQ: RVPH) ha informado avances significativos en su programa de desarrollo de brilaroxazina para el tratamiento de la esquizofrenia y sus resultados financieros del segundo trimestre de 2025. La compa帽铆a complet贸 con 茅xito el estudio de extensi贸n abierta (OLE) de 1 a帽o de la Fase 3 RECOVER, mostrando eficacia sostenida en todos los dominios de s铆ntomas y un perfil de seguridad bien tolerado.
Entre los logros cl铆nicos clave figura una robusta eficacia de amplio espectro con mejoras en la puntuaci贸n PANSS total (-18,1), en los s铆ntomas positivos (-5,0) y en los negativos (-4,4). La empresa planea reunirse con la FDA en el cuarto trimestre de 2025 para abordar la v铆a hacia la aprobaci贸n, con la posible presentaci贸n de una NDA prevista para el segundo trimestre de 2026.
En lo financiero, Reviva report贸 una p茅rdida neta de 6,1 millones de d贸lares (0,12$ por acci贸n) en el Q2 de 2025, frente a 7,9 millones en el Q2 de 2024. La posici贸n de efectivo asciende a 10,4 millones de d贸lares, reforzada por una reciente oferta p煤blica de acciones por 10,0 millones de d贸lares.
Reviva Pharmaceuticals (NASDAQ: RVPH)電� 臁绊槃氤� 旃橂鞝� 敫岆Υ霛茧靷(Brilaroxazine) 臧滊皽 頂勲攴鸽灗鞐愳劀 欷戩殧頃� 歆勳爠鞚� 氤搓碃頃橁碃 2025雲� 2攵勱赴 鞛鞁れ爜鞚� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 3靸� RECOVER 瓿店皽鞐办灔(OLE) 1雲� 鞐瓣惮毳� 靹标车鞝侅溂搿� 鞕勲頄堨溂氅�, 氇摖 歃濎儊 鞓侅棴鞐愳劀 歆�靻嶌爜鞚� 須姤瓿� 鞏戫樃頃� 雮挫暯靹膘潣 鞎堨爠靹� 頂勲韺岇澕鞚� 鞛呾頄堨姷雼堧嫟.
欤检殧 鞛勳儊 靹标臣搿滊姅 PANSS 齑濎爯(-18.1), 鞏戩劚 歃濎儊(-5.0), 鞚岇劚 歃濎儊(-4.4)鞐愳劀鞚� 臧滌劆鞚� 韽暔頃� 甏戨矓鞙勴晿瓿� 臧曤牓頃� 須姤鞚� 鞛堨姷雼堧嫟. 須岇偓電� 鞀轨澑 瓴诫毳� 雲检潣頃橁赴 鞙勴暣 2025雲� 4攵勱赴鞐� FDA鞕� 須岇潣毳� 臧�歆� 瓿勴殟鞚措┌, 2026雲� 2攵勱赴 NDA 鞝滌稖鞚� 氇╉憸搿� 頃橁碃 鞛堨姷雼堧嫟.
鞛鞝侅溂搿� Reviva電� 2025雲� 2攵勱赴鞐� 靾滌啇鞁� 610毵� 雼煬(欤茧嫻 0.12雼煬)毳� 氤搓碃頄堨溂氅�, 鞚措姅 2024雲� 2攵勱赴鞚� 790毵� 雼煬鞐� 牍勴暣 臧愳唽頃� 靾橃箻鞛呺媹雼�. 順勱笀 氤挫湢鞎§潃 斓滉芳 1000毵� 雼煬鞚� 瓿惦 鞛愱笀 頇曤炒搿� 1040毵� 雼煬鞛呺媹雼�.
Reviva Pharmaceuticals (NASDAQ: RVPH) a annonc茅 des progr猫s significatifs dans son programme de d茅veloppement de la brilaroxazine pour le traitement de la schizophr茅nie, ainsi que ses r茅sultats financiers du deuxi猫me trimestre 2025. La soci茅t茅 a men茅 脿 bien l'茅tude d'extension en ouvert (OLE) d'un an de la Phase 3 RECOVER, d茅montrant une efficacit茅 soutenue sur tous les domaines symptomatiques et un profil de s茅curit茅 bien tol茅r茅.
Parmi les principales avanc茅es cliniques figurent une efficacit茅 large et robuste avec des am茅liorations du score total PANSS (-18,1), des sympt么mes positifs (-5,0) et des sympt么mes n茅gatifs (-4,4). La soci茅t茅 pr茅voit de rencontrer la FDA au 4e trimestre 2025 pour discuter de la voie d'approbation, avec une 茅ventuelle soumission de NDA cibl茅e au 2e trimestre 2026.
Sur le plan financier, Reviva a affich茅 une perte nette de 6,1 millions de dollars (0,12 $ par action) au T2 2025, contre 7,9 millions au T2 2024. La tr茅sorerie s'茅l猫ve 脿 10,4 millions de dollars, soutenue par une r茅cente lev茅e de fonds publique de 10,0 millions de dollars.
Reviva Pharmaceuticals (NASDAQ: RVPH) hat bedeutende Fortschritte in seinem Entwicklungsprogramm f眉r Brilaroxazin zur Behandlung von Schizophrenie gemeldet und die Finanzergebnisse f眉r das 2. Quartal 2025 ver枚ffentlicht. Das Unternehmen schloss die offene Verl盲ngerungsstudie (OLE) der Phase鈥�3鈥慡tudie RECOVER 眉ber ein Jahr erfolgreich ab und zeigte anhalte Wirksamkeit in allen Symptombereichen sowie ein gut vertr盲gliches Sicherheitsprofil.
Zu den wichtigsten klinischen Ergebnissen z盲hlen eine robuste breit angelegte Wirksamkeit mit Verbesserungen im PANSS鈥慓esamtwert (-18,1), bei positiven Symptomen (-5,0) und bei negativen Symptomen (-4,4). Das Unternehmen plant, sich im 4. Quartal 2025 mit der FDA zu treffen, um den Zulassungsweg zu besprechen, mit einer m枚glichen NDA鈥慐inreichung im 2. Quartal 2026.
Finanziell verzeichnete Reviva im 2. Quartal 2025 einen Nettogewinnverlust von 6,1 Mio. USD (0,12 USD je Aktie), gegen眉ber 7,9 Mio. USD im Q2 2024. Die liquiden Mittel belaufen sich auf 10,4 Mio. USD, gest眉tzt durch ein j眉ngstes 枚ffentliches Aktienangebot in H枚he von 10,0 Mio. USD.
- Successful completion of Phase 3 RECOVER open-label extension trial showing sustained efficacy over 1 year
- Improved PANSS scores across all symptom domains including negative symptoms
- Reduced quarterly net loss from $7.9M in Q2 2024 to $6.1M in Q2 2025
- Raised $10.0M through public equity offering
- Patent portfolio potentially extending to 2045 and beyond
- 35% discontinuation rate in 1-year trial
- Cash position decreased from $13.5M in December 2024 to $10.4M in June 2025
- Additional Phase 3 RECOVER-2 trial may be required pending FDA feedback
Insights
Reviva's brilaroxazine shows promising 1-year safety/efficacy data for schizophrenia, positioning for potential NDA filing in Q2 2026.
Reviva has reached a significant milestone with the successful completion of its 1-year open-label extension (OLE) trial for brilaroxazine in schizophrenia. The data package now includes two large randomized double-blind trials (Phase 2 and Phase 3), a 1-year OLE trial, and supporting clinical pharmacology studies鈥攅ssentially completing the clinical requirements for FDA submission.
The OLE results demonstrate sustained efficacy across all symptom domains, with meaningful improvements in the challenging-to-treat negative symptoms (PANSS negative symptom reduction of -4.4 points). This is particularly noteworthy as negative symptoms often remain resistant to current antipsychotics and significantly impact functional outcomes and quality of life.
The discontinuation rate of 35% over one year suggests reasonable tolerability compared to typical attrition rates for antipsychotics. Most importantly, this completed data package has given the company confidence to seek an FDA meeting in Q4 2025 to potentially bypass the planned RECOVER-2 trial and proceed directly to NDA submission by Q2 2026.
The company is simultaneously expanding its intellectual property portfolio with patents potentially extending to 2045, which would provide crucial market exclusivity well beyond the initial approval. Additionally, Reviva is exploring a novel liposomal-gel formulation of brilaroxazine for psoriasis, suggesting potential for label expansion into inflammatory conditions鈥攁 strategically sound approach to maximize the commercial potential of their lead compound.
Positive clinical progress coupled with narrowing losses and $10.4M cash position creates cautious optimism amid upcoming regulatory milestones.
Reviva's financial position shows some improvement with quarterly losses narrowing to
The current cash position stands at
While no explicit cash runway guidance was provided, pharmaceutical companies typically require significant capital for NDA submissions and pre-commercial activities. With quarterly cash burn likely in the
The company's pursuit of partnership opportunities for pipeline development is strategically sound, as it could provide non-dilutive capital while leveraging external expertise. A successful FDA meeting in Q4 2025 potentially eliminating the need for an additional Phase 3 trial would significantly reduce future capital requirements and accelerate the timeline to potential commercialization鈥攔epresenting a crucial inflection point for investor sentiment.
鈥� Well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms in open label extension (OLE) 1-year trial鈥�
鈥� Successful completion of two large randomized double-blind clinical trials, including one Phase 2 and one Phase 3 trial, a 1-year OLE trial, and clinical pharmacology studies designed to support filing of New Drug Application (NDA) 鈥�
鈥� Planned meeting with Food and Drug Administration (FDA) to discuss brilaroxazine鈥檚 path to approval for schizophrenia in Q4 2025; potential NDA submission targeted for Q2 2026 鈥�
CUPERTINO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (鈥淩eviva鈥� or the 鈥淐ompany鈥�), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today reported financial results for the second quarter ended June 30, 2025 and summarized recent business highlights.
鈥淭he successful completion of our global OLE 1-year trial marks a major milestone for the brilaroxazine program as we advance toward potential registration,鈥� said Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva. 鈥淭his comprehensive dataset reinforces our prior positive clinical results and highlights the long-term safety, broad-spectrum sustained efficacy, and strong adherence profile of once daily brilaroxazine. We believe all key clinical data required for NDA are completed and we are preparing for an End-of-Phase 3 meeting with the FDA planned in the fourth quarter of the year to discuss our future NDA submission based on the current data package and excluding the planned Phase 3 RECOVER-2 trial. Pending favorable feedback from the FDA, we will target an NDA submission in the second quarter of 2026. Brilaroxazine continues to demonstrate a differentiated and durable clinical profile, positioning it as a potential new standard of care in schizophrenia and a meaningful driver of long-term value.鈥�
Second Quarter 2025 and Recent Business Highlights
Clinical Program and Business Highlights
- Announced a positive full dataset and successful completion of the Company鈥檚 Phase 3 RECOVER open-label extension (OLE) 1-year study evaluating the long-term safety, tolerability and efficacy of brilaroxazine in patients with schizophrenia
- Once daily brilaroxazine (pooled 15, 30, and 50 mg, N=446) led to robust broad-spectrum efficacy that was sustained over 1-year including PANSS total score (鈥�18.1), positive symptoms (鈥�5.0), negative symptoms (鈥�4.4) and negative Marder factor (-4.4)
- Generally well tolerated with a discontinuation rate of
35% after 1-year for pooled doses of brilaroxazine (pooled 15, 30, and 50 mg, N=446)
- Continuing efforts aimed at expansion of strong diversified patent portfolio comprising composition of matter and lifecycle management strategies for innovative formulations and method of treatment for different major indications with clear regulatory path including potential patent and/or market exclusivity up to 2045 and beyond.
- Presented a late-breaking poster presentation on the RECOVER 12-month OLE trial for brilaroxazine in schizophrenia at the 2025 American Society of Clinical Psychopharmacology (ASCP) annual meeting on Wednesday May 28, 2025, in Scottsdale, AZ.
- Completed public equity offering raising gross proceeds of
$10.0 million , before deducting placement agent fees and other offering expenses.
Anticipated Milestones and Events
- Planned meeting with FDA to discuss brilaroxazine鈥檚 path to approval in Q4 2025
- Potential NDA submission for brilaroxazine in schizophrenia targeted in Q2 2026
- Plans are being assessed to initiate a potential registrational Phase 3 RECOVER-2 trial evaluating brilaroxazine for the treatment of schizophrenia pending FDA recommendation for a path to approval
- Investigational new drug application (IND) submission for liposomal-gel formulation of brilaroxazine in psoriasis expected by Q2- 2026
- Pursuing partnership opportunities for the development of our pipeline
Financial Results for June 30, 2025
- The Company reported a net loss of approximately
$6.1 million , or$0.12 per share, for the three months ended June 30, 2025, compared to a net loss of approximately$7.9 million , or$0.26 per share, for the three months ended June 30, 2024. - As of June 30, 2025, the Company鈥檚 cash and cash equivalents totaled approximately
$10.4 million compared to approximately$13.5 million as of December 31, 2024.
About Reviva听
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva鈥檚 current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva鈥檚 pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, including those relating to the Company鈥檚 plans for its brilaroxazine program including intended steps towards potential approval, the Company鈥檚 plans for meeting with FDA and plans for potential NDA submission, the Company鈥檚 statements regarding assessment of plans for a potential registrational Phase 3 RECOVER-2 trial evaluating brilaroxazine for the treatment of schizophrenia, if required, statements about potential IND submissions, the Company鈥檚 expectations regarding the anticipated clinical profile of its product candidates, including statements regarding anticipated efficacy or safety profile, and those relating to the Company鈥檚 expectations, intentions or beliefs regarding matters including product development and clinical trial plans and the timing thereof, including the anticipated timing of the availability of trial data, clinical and regulatory timelines and expenses, planned or intended additional trials or studies and the timing thereof, planned or intended regulatory submissions and the timing thereof, trial results, market opportunity, ability to raise sufficient funding, competitive position, possible or assumed future results of operations, business strategies, potential opportunities for development including partnerships, growth or expansion opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management鈥檚 current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, 鈥渆xpect,鈥� 鈥渁nticipate,鈥� 鈥渋ntend,鈥� 鈥減lan,鈥� 鈥渂elieve,鈥� 鈥渆stimate,鈥� 鈥減otential, 鈥減redict,鈥� 鈥減roject,鈥� 鈥渟hould,鈥� 鈥渨ould鈥� and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company鈥檚 most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and the Company鈥檚 other filings from time to time with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
| 听 | 听 | 听 | 听 | ||||
| REVIVA PHARMACEUTICALS HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) | |||||||
| 听 | 听 | 听 | 听 | ||||
| 听 | June 30, | 听 | December 31, | ||||
| 听 | 听2025听 | 听 | 听2024听 | ||||
| Assets | 听 | 听 | 听 | ||||
| Cash and cash equivalents | $ | 10,363,714 | 听 | 听 | $ | 13,476,331 | 听 |
| Prepaid clinical trial costs | 听 | 104,447 | 听 | 听 | 听 | 540,601 | 听 |
| Prepaid expenses and other current assets | 听 | 346,964 | 听 | 听 | 听 | 666,435 | 听 |
| Total current assets | 听 | 10,815,125 | 听 | 听 | 听 | 14,683,367 | 听 |
| Non-current prepaid clinical trial costs | 听 | 819,721 | 听 | 听 | 听 | 819,721 | 听 |
| Total Assets | $ | 11,634,846 | 听 | 听 | $ | 15,503,088 | 听 |
| 听 | 听 | 听 | 听 | ||||
| Liabilities and Stockholders鈥� Equity (Deficit) | 听 | 听 | 听 | ||||
| 听 | 听 | 听 | 听 | ||||
| Liabilities | 听 | 听 | 听 | ||||
| Short-term debt | $ | 113,246 | 听 | 听 | $ | 458,154 | 听 |
| Accounts payable | 听 | 4,968,688 | 听 | 听 | 听 | 6,283,430 | 听 |
| Accrued clinical expenses | 听 | 5,470,185 | 听 | 听 | 听 | 6,723,719 | 听 |
| Accrued compensation | 听 | 602,592 | 听 | 听 | 听 | 635,587 | 听 |
| Other accrued liabilities | 听 | 922,592 | 听 | 听 | 听 | 500,616 | 听 |
| Total current liabilities | 听 | 12,077,303 | 听 | 听 | 听 | 14,601,506 | 听 |
| Warrant liabilities | 听 | 16,690 | 听 | 听 | 听 | 89,010 | 听 |
| Total Liabilities | 听 | 12,093,993 | 听 | 听 | 听 | 14,690,516 | 听 |
| 听 | 听 | 听 | 听 | ||||
| Commitments and contingencies | 听 | 听 | 听 | ||||
| 听 | 听 | 听 | 听 | ||||
| Stockholders鈥� Equity (Deficit) | 听 | 听 | 听 | ||||
| Common stock, par value of | 听 | 6,800 | 听 | 听 | 听 | 4,658 | 听 |
| Preferred Stock, par value of | 听 | 鈥� | 听 | 听 | 听 | 鈥� | 听 |
| Additional paid-in capital | 听 | 176,293,553 | 听 | 听 | 听 | 165,080,964 | 听 |
| Accumulated deficit | 听 | (176,759,500 | ) | 听 | 听 | (164,273,050 | ) |
| Total stockholders' equity (deficit) | 听 | (459,147 | ) | 听 | 听 | 812,572 | 听 |
| 听 | 听 | 听 | 听 | ||||
| Total Liabilities and Stockholders鈥� Equity (Deficit) | $ | 11,634,846 | 听 | 听 | $ | 15,503,088 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) | |||||||||||||||
| 听 | 听 | 听 | 听 | ||||||||||||
| 听 | Three Months Ended June 30, | 听 | Six Months Ended June 30, | ||||||||||||
| 听 | 听 | 2025 | 听 | 听 | 听 | 2024 | 听 | 听 | 听 | 2025 | 听 | 听 | 听 | 2024 | 听 |
| Operating expenses | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Research and development | $ | 3,724,755 | 听 | 听 | $ | 5,584,347 | 听 | 听 | $ | 7,838,292 | 听 | 听 | $ | 11,368,212 | 听 |
| General and administrative | 听 | 2,348,227 | 听 | 听 | 听 | 2,545,296 | 听 | 听 | 听 | 4,772,857 | 听 | 听 | 听 | 4,683,537 | 听 |
| Total operating expenses | 听 | 6,072,982 | 听 | 听 | 听 | 8,129,643 | 听 | 听 | 听 | 12,611,149 | 听 | 听 | 听 | 16,051,749 | 听 |
| Loss from operations | 听 | (6,072,982 | ) | 听 | 听 | (8,129,643 | ) | 听 | 听 | (12,611,149 | ) | 听 | 听 | (16,051,749 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Other income (expense) | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Gain on remeasurement of warrant liabilities | 听 | 11,126 | 听 | 听 | 听 | 200,273 | 听 | 听 | 听 | 72,320 | 听 | 听 | 听 | 656,450 | 听 |
| Interest expense | 听 | (4,797 | ) | 听 | 听 | (5,153 | ) | 听 | 听 | (16,417 | ) | 听 | 听 | (8,640 | ) |
| Interest income | 听 | 22,847 | 听 | 听 | 听 | 87,610 | 听 | 听 | 听 | 108,958 | 听 | 听 | 听 | 260,708 | 听 |
| Other (expense) income, net | 听 | (1,850 | ) | 听 | 听 | (5,621 | ) | 听 | 听 | (26,995 | ) | 听 | 听 | (135,515 | ) |
| Total other (expense) income, net | 听 | 27,326 | 听 | 听 | 听 | 277,109 | 听 | 听 | 听 | 137,866 | 听 | 听 | 听 | 773,003 | 听 |
| Loss before provision for income taxes | 听 | (6,045,656 | ) | 听 | 听 | (7,852,534 | ) | 听 | 听 | (12,473,283 | ) | 听 | 听 | (15,278,746 | ) |
| Provision for income taxes | 听 | 7,954 | 听 | 听 | 听 | 7,385 | 听 | 听 | 听 | 13,167 | 听 | 听 | 听 | 14,781 | 听 |
| Net loss | $ | (6,053,610 | ) | 听 | $ | (7,859,919 | ) | 听 | $ | (12,486,450 | ) | 听 | $ | (15,293,527 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Net loss per share: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Basic and diluted | $ | (0.12 | ) | 听 | $ | (0.26 | ) | 听 | $ | (0.25 | ) | 听 | $ | (0.51 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Weighted average shares outstanding | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Basic and diluted | 听 | 49,847,872 | 听 | 听 | 听 | 30,555,012 | 听 | 听 | 听 | 49,249,430 | 听 | 听 | 听 | 30,221,168 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
FAQ
What were the key findings from Reviva's Phase 3 RECOVER trial for brilaroxazine?
When does Reviva (RVPH) plan to submit its NDA for brilaroxazine?
What was Reviva's (RVPH) financial position in Q2 2025?
What is the patent protection timeline for Reviva's brilaroxazine?
What are the next major milestones for Reviva (RVPH)?
